Track topics on Twitter Track topics that are important to you
Regenerative medicines specialist WideCells Group PLC (LON:WDC) said it had been granted a research licence from the UK's Human Tissue Authority, which chief executive João Andrade said opened up a “new dimension” for the company. Specifically, it paves the way to a collaboration with Qigenix, which is assessing the potential to activate stem cells using lasers. WideCells will receive £100,000 as part of the tie-up. Additionally, the firm will carry out its own in-house research to develop new technology using WideCells' artificial bone product INDUS, together with mesenchymal stem cells to enable significantly faster bone formation. The work will be carried out at the WideCells Institute of Stem Cell Technology (ISCT), at the University of Manchester Innovation Centre, which is led by the firm’s chief scientific officer, Dr Peter Hollands. CEO Andrade said of Monday’s announcement: "This licence opens up yet another dimension for us as we continue to work at the forefront of the stem cell industry in expanding our research division. “We recently launched our innovative INDUS product, a new artificial bone material which targets the dental market; however now with this licence in place, we can expand our innovative research across a wider field. “Our research division will now be in a revenue generative position, alongside CellPlan our medical insurance product, thereby strengthening our overall financial position. “I am delighted with the position of the company at it stands, and I look forward to providing further news in the near term on our rapid development and product roll out."NEXT ARTICLE
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...
Track and monitor developments in stem cell research and commercial development. Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry. BioPort...